P53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Novello, Chiara ^a   Pazzaglia, Laura ^a   Conti, Amalia ^a   Quattrini, Irene ^a   Pollino, Serena ^a,b   Perego, Paola ^c   Picci, Piero ^a   Benassi, Maria Serena ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; ETOPOSIDE; MICRORNA 34A; PROTEIN P53; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; MESSENGER RNA; MICRORNA; MIRN34 MICRORNA, HUMAN; TP53 PROTEIN, HUMAN;

ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; DRUG SENSITIVITY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PROMOTER REGION; PROTEIN EXPRESSION; RNA METHYLATION; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BONE NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DNA METHYLATION; DOMINANT GENE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; BONE NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DNA DAMAGE; DNA METHYLATION; ETOPOSIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, DOMINANT; HUMANS; MICRORNAS; MOLECULAR SEQUENCE DATA; MUTATION; OSTEOSARCOMA; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEQUENCE HOMOLOGY, NUCLEIC ACID; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84916920091     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114757     Document Type: Article

References (33)

1. Klein MJ, Siegal GP (2006) Osteosarcoma: anatomic and histologic variants. Am J Clin Pathol 125: 555-581.
2. Gorlick R, Khanna C (2010) Osteosarcoma. JBMR 25: 683-691.
3. Gougelet A, Pissaloux D, Besse A, Perez J, Duc A, et al. (2011) Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. Int J Cancer, 129(3): 680-690.
4. D'Adamo DR (2011) Appraising the current role of chemotherapy for the treatment of sarcoma. Semin Oncol (Suppl 3): S19-29.
5. ESMO/European Sarcoma Network Working Group (2012) Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (Suppl 7): vii100-9.
6. Ezoe S (2012) Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. IJERPH 9(7): 2444-2453.
7. Montecucco A, Biamonti G (2007) Cellular response to etoposide treatment. Cancer Letters 252(1): 9-18.
8. Fitzgibbon C, Ihmaid S, Al-Rawi J, Meehan-Andrews T, Bradley C (2013) Chemo-sensitisation of HeLa cells to Etoposide by a Benzoxazine in the absence of DNA-PK inhibition. Invest New Drugs 31(6): 1466-75.
9. Ling B, Wei-Guo Z (2006) P53: Structure, function and therapeutic application. Journal of Cancer Molecules 2(4): 141-153.
10. Melo S, Esteller M (2011) Dysregulation of microRNAs in cancer: playing with fire. FEBS letters 585(13): 2087-99.
11. Garzon R, Fabbri M, Cimmino A, Calin G, Croce CM (2006) MicroRNA expression and function in cancer. Trends in Molecular Medicine 12(12): 580-587.
12. He X, He L, Hannon GJ (2007) The guardian's little helper: microRNAs in the p53 tumor suppressor network. Cancer Res 67(23): 11099-11101.
13. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, et al. (2007) Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: MiR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6: 1586-1593.
14. He C, Xiong J, Xu X, Lu W, Liu L, et al. (2009) Functional elucidation of MiR-34 in osteosarcoma cells and primary tumor samples. BBRC 388(1): 35-40.
15. Chen F, Hu SY (2012) Effect of microRNA-34a in cell cycle, differentiation, and apoptosis: a rewiew. J Biochem Mol Toxicol 26 (2): 79-86.
16. Mraz M, Malinova K, Kotaskova J, Pavlova S, Tichy B, et al. (2009) miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia 23(6): 1159-1163.
17. Ellis L, Atadja PW, Johnstone RW (2009) Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 8: 1409-1420.
18. Mikeska T, Bock C, Do H, Dobrovic A (2012) DNA methylation biomarkers in cancer: progress towards clinical implementation. Expert Rev Mol Diagn 12(5): 473-487.
19. McCabe MT, Brandes JC, Vertino PM (2009) Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res 15: 3927-3937.
20. Gatti L, Supino R, Perego P, Pavesi R, Caserini C, et al. (2002) Apoptosis and growth arrest induced by platinum compounds in U2-OS cells reflect a specific DNA damage recognition associated with a different p53-mediated response. Cell Death Differentiation 9: 1352-1359.
21. Agostini M, Knight RA (2014) miR-34: from bench to bedside. Oncotarget 5(4): 872-81.
22. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H (2007) Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A. 104(39): 15472-7.
23. Yan K, Gao J, Yang T, Ma Q, Qiu X, et al. (2012) MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PloS One 7(3), e33778.
24. Ji Q, Hao X, Zhang M, Tang W, Yang M, et al. (2009) MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. Plos One 4(8): e6816.
25. Zhu JJ, Li FB, Zhu XF, Liao WM (2006) The p33ING1b tumor suppressor cooperates with p53 to induce apoptosis in response to etoposide in human osteosarcoma cells. Life Sci 78(13): 1469-77.
26. Tsang W, Ho FYF, Fung K, Kong S, Kwok T (2005) p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis. Int J Cancer 114(3): 331-6.
27. Petitjean A, Mathe E, Kato S, Ishioka C, Sean V, et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 Database. Hum Mutat 28(6): 622-9.
28. Lang GA, Iwakuma T, Suh Y-A, Liu G, Rao VA, et al. (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119(6): 861-72.
29. Lujambio A, Calin GA, Villanueva A, Ropero S, Sánchez-Céspedes M, et al. (2008) microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A 105(36): 13556-13561.
30. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, et al. (2008) Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7(16): 2591-2600.
31. Chim CS, Wan TS, Wong KY, Fung TK, Drexler HG, et al. (2011) Methylation of miR-34a, miR-34b/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms. J Transl Med 9: 197.
32. Kawabe T (2004) G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 3: 513-519.
33. De Vries A, Flores ER, Miranda B, Hsieh H-M, van Oostrom CthM, et al. (2002) Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. PNAS 99(5): 2948-2953.